Fibrobiologics(FBLG.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Fibrobiologics
FBLG.US
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.
1.880 T
FBLG.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market movement update: Real estate stocks lead the rise, Wheeler Real Estate up over 31%, biotechnology stocks generally decline

    Overview of the US Stock Market In the past hour, the US stock market has shown significant sector rotation characteristics, with the real estate and technology sectors performing particularly well. Wheeler Real Estate led the gains, driving the overall rise of the real estate sector, while in the tech stocks, the strong performance of Fathom and Icon Energy also attracted market attention. Fund flows indicate that investors prefer small-cap stocks and thematic stocks, with short-term enthusiasm clearly increasing and market sentiment active. The stock with the largest movement in the past hour, Wheeler Real Estate, became the market focus with a 31.15% increase. Its strong upward momentum not only reflects the overall activity of the real estate sector but also shows investors' optimistic expectations for the stock's future growth potential. The rapid inflow of funds has increased the stock's volatility, significantly enhancing the participation of short-term traders. Strong stocks: 1. Fathom: Up 19.23%, standing out in the technology sector, with active short-term fund involvement driving rapid price increases. 2. Icon Energy: Up 18.01%, benefiting from the overall recovery of the energy sector, with the market holding an optimistic view of its future development. 3. Revolution Medicines: Up 13.07%, supported by the continued strength of the pharmaceutical sector. 4. Opendoor Tech: Up 12.60%, with the active real estate market driving the stock's strong performance

    Tracking Unusual Activity·
    US
    FBLG
    -0.77%
    Tracking Unusual Activity·
    US
    FBLG
    -0.77%

    Pre-market hot trades in US stocks: Positive clinical trial news fails to boost Fibrobiologics, which falls 7.79% in pre-market trading, raising market concerns

    Fibrobiologics pre-market down 7.79%; Aclarion pre-market up 41.57%; A SPAC III Acquisition pre-market up 33.11%; CIMG pre-market up 29.63%

    Tracking Unusual Activity·
    US
    FBLG
    -0.77%
    Tracking Unusual Activity·
    US
    FBLG
    -0.77%

    FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference

    FibroBiologics Inc., a clinical-stage biotechnology company, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026, at 4:30 p.m. PT in San Francisco. The company focuses on developing therapeutics for chronic diseases using fibroblast technology. This news was generated by Public Technologies and is for informational purposes only, not financial or legal advice.

    Reuters·
    US
    FBLG
    -0.77%
    Reuters·
    US
    FBLG
    -0.77%

    Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy

    Jan 5 (Reuters) - Fibrobiologics Inc:* FIBROBIOLOGICS ANNOUNCES POSITIVE PRECLINICAL RESULTS FOR A FIBROBLAST SPHEROID-DERIVED CHONDROCYTE (FSDC) SPHEROID THERAPY FOR DEGENERATIVE DISC DISEASE Source text: Further company coverage:

    Reuters·
    US
    FBLG
    -0.77%
    Reuters·
    US
    FBLG
    -0.77%

    FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease

    FibroBiologics Inc. has reported positive preclinical results for its FSdC therapy aimed at treating degenerative disc disease. The therapy demonstrated significant improvements in disc preservation and structural integrity in animal models, indicating its potential for regenerative effects. The company plans to move forward with clinical development in collaboration with regulatory authorities, although the results have not yet been presented at a scientific meeting.

    Reuters·
    US
    FBLG
    -0.77%
    Reuters·
    US
    FBLG
    -0.77%
    © 2026 Longbridge｜Disclaimer